Supplier risk classification is the process of sorting your supply base into tiers based on the potential impact each supplier has on product quality, patient safety, and regulatory compliance. FDA QMSR (21 CFR Part 820) and ISO 13485 both require that purchasing controls be proportional to risk. That means Tier 1 critical suppliers receive intensive qualification, regular audits, and close performance monitoring, while lower-risk suppliers receive a lighter touch. Without a documented tiering system, quality teams either over-invest in low-risk vendor management or under-control the suppliers who matter most. Both outcomes create problems.

What is supplier risk classification?

Supplier risk classification assigns each supplier in your supply base to a risk tier based on a defined set of criteria. The tier determines how the supplier is qualified, how often they are audited, what performance data is tracked, and what happens when they have a nonconformance.

The classification is not permanent. A supplier’s tier can change as their performance record accumulates, as the materials they supply change, or as the company’s understanding of the risk profile evolves. A supplier who was classified as Tier 2 on initial qualification may be elevated to Tier 1 if a subsequent design change makes their material more critical to device safety.

Supplier quality management built around a formal tiering system is far more efficient than a flat approach that treats every supplier identically. The tiering system directs quality resources toward the suppliers where the consequences of a quality failure are greatest.

The regulatory basis for risk-based supplier controls

FDA QMSR Section 820.50 requires that the type and extent of control exercised over suppliers, contractors, and consultants be commensurate with the risk associated with the purchased product or service. This language explicitly creates the regulatory basis for a tiered supplier management approach. FDA does not require the same level of control over every supplier; it requires appropriate control based on risk.

ISO 13485 Section 7.4.1 uses similar language: the type and extent of control applied to the supplier must be based on the effect of the purchased product or service on the subsequent realization of product. The ISO standard also requires that evaluation criteria be established in documented procedures.

The practical implication of both requirements: a tiering system must exist in writing. It cannot be an informal understanding that some suppliers are more important than others. The criteria used to classify each supplier, and the controls that apply to each tier, must be documented in a procedure that is approved through the quality system.

Defining tiering criteria: what factors drive classification

Tiering criteria vary by industry and product type, but the core factors are consistent across regulated manufacturing:

Impact on product quality attributes

Materials or services that directly determine whether the finished product meets its critical quality attributes (CQAs) carry the highest risk. An API supplier whose product becomes the active ingredient in a drug product, or a contract sterilizer whose process defines the sterility assurance level of a medical device, has direct and irreplaceable impact on product quality. These are always Tier 1.

Regulatory specificity of the supply

Some suppliers are named in regulatory submissions. If a pharmaceutical drug product’s NDA or ANDA names a specific API manufacturer, changing that supplier requires a regulatory filing. The regulatory entrenchment of a supplier increases the risk of supply disruption and the consequence of quality failure. Named regulatory suppliers are Tier 1 by definition.

Uniqueness and substitutability

A supplier providing a highly specialized material or service with few or no qualified alternatives carries higher business risk than a supplier of a commodity material available from multiple qualified sources. Single-source or sole-source suppliers need closer management regardless of their material’s direct quality impact, because losing them creates supply disruption risk.

Regulatory certification status

Suppliers who hold relevant quality system certifications (ISO 9001, ISO 13485, GMP certification, or equivalent) demonstrate a baseline level of quality management maturity. Suppliers without certifications require more intensive qualification and monitoring to compensate for the absence of a third-party-verified quality system.

Historical performance

A supplier’s nonconformance rate, complaint history, SCAR response record, and on-time delivery history over the past one to three years are all relevant inputs to tiering decisions. A supplier who initially qualifies as Tier 2 based on material criticality may be elevated to closer oversight if their performance record is consistently poor.

A practical three-tier model

Most regulated manufacturers use a three-tier model, though some companies use four tiers or apply different labels. The logic is consistent regardless of the naming convention.

Tier 1: Critical suppliers

Tier 1 suppliers provide materials or services that have a direct, significant impact on product safety, efficacy, or regulatory compliance. Loss of supply from a Tier 1 supplier would disrupt manufacturing or require a regulatory submission before an alternative could be used.

Qualification requirements for Tier 1 typically include: completion of a detailed supplier questionnaire, review of quality system certifications and regulatory compliance history, an on-site audit before initial approval, review of first-article or first-lot data against specification, and a formal qualification decision approved by quality management.

Ongoing monitoring for Tier 1 includes: annual performance review with documented scoring, on-site re-audit every one to three years depending on performance, mandatory review of supplier change notifications before changes take effect, and escalation of any nonconformance through the SCAR process with defined response timelines.

Tier 2: Major suppliers

Tier 2 suppliers provide materials with a defined but indirect quality impact. Their materials do not directly determine critical quality attributes, but failures in supply could affect the manufacturing process or product characteristics in ways that require investigation and corrective action.

Qualification for Tier 2 typically includes: a supplier questionnaire, review of quality certifications, and a desk review of the supplier’s quality system documentation. On-site audits are not mandatory for Tier 2 but may be conducted if the qualification review raises questions that cannot be answered remotely.

Ongoing monitoring for Tier 2 includes: annual performance review, periodic review of quality certification currency, and SCAR issuance for significant nonconformances. Re-audit is triggered by performance decline or a major nonconformance rather than on a fixed schedule.

Tier 3: Standard suppliers

Tier 3 suppliers provide low-risk materials or services with minimal direct quality impact. Their materials are typically indirect process materials, laboratory consumables for non-critical tests, or support services that do not directly contact the product or affect product quality attributes.

Qualification for Tier 3 typically involves reviewing quality certifications, confirming the supplier can meet specifications, and conducting incoming inspection to confirm material quality. Formal on-site audits are generally not required.

Ongoing monitoring for Tier 3 is light: incoming inspection data provides the primary performance signal, and the supplier’s ASL status is reviewed annually without a formal performance scoring process.

Documenting the tiering decision

Every supplier’s tier classification must be documented in their qualification record. The documentation must include which criteria were applied, what assessment was made against each criterion, and what tier the assessment produced. “We classified them as Tier 2” with no supporting rationale does not satisfy regulatory expectations.

The tiering decision should be approved by the quality function and recorded in the supplier’s file. If the classification is borderline, for example, a material that sits on the line between Tier 1 and Tier 2, the quality team’s deliberation and the rationale for the final decision should also be documented.

When a supplier’s tier changes, the change must be documented as part of the supplier’s performance record, with the reason for the change and any new controls that apply following the reclassification.

Integrating tiering with purchasing controls

The tiering system is only useful if it connects to the purchasing process. Purchase orders for Tier 1 materials should require quality review and confirmation of ASL status before issuance. Tier 2 and Tier 3 materials may follow a lighter purchasing review, consistent with their lower risk classification.

For companies that manage a large supply base, manual purchasing reviews for every order are not realistic. A QMS that surfaces the supplier’s tier and ASL status at the point of purchase order creation makes the quality check automatic without requiring the purchasing team to manually consult the ASL each time.

Using tiering data in management review

Supplier risk classification generates data that belongs in the management review process. ISO 13485 Section 5.6 and FDA QMSR both require that management review include information on supplier and contractor performance. The tiering system provides the framework for presenting that information meaningfully: how many Tier 1 suppliers had nonconformances this period, what is the average SCAR response time by tier, how many Tier 1 suppliers are due for re-audit in the next six months?

Without a tiering system, supplier performance data in management review is a flat list of incidents with no context. With tiering, leadership can assess whether quality risk in the supply chain is concentrated in critical or low-risk areas and direct resources accordingly.

Common tiering mistakes to avoid

Classifying by spend, not by risk. High-spend suppliers are not necessarily high-risk suppliers. A company’s largest vendor by purchase volume may supply commodity materials with multiple qualified alternatives, while a small specialist supplier may provide a sole-source critical component with no substitute. Tier classification must be based on quality and regulatory risk, not purchasing volume.

Classifying all suppliers as Tier 1 to be safe. When tiering criteria are vague, quality teams sometimes classify all suppliers as Tier 1 to avoid any risk of under-controlling a critical supplier. The result is an audit program that the quality team cannot resource, with annual on-site audits required for dozens of suppliers. Defensible tiering criteria prevent this outcome by providing a principled basis for assigning suppliers to appropriate tiers.

Failing to reclassify after product or process changes. A supplier classified as Tier 3 when their material was used in a low-risk step may need to be reclassified if that step is modified and the material becomes more critical. The tiering system must include a trigger to review supplier classifications when significant changes occur in the manufacturing process or product design.

No documented basis for the classification. A supplier list with tier labels but no qualification records showing how each supplier was assessed against the tiering criteria is not a defensible tiering system. The documentation is what transforms the tiering concept into a regulatory control.

How Cloudtheapp supports supplier risk tiering

Cloudtheapp’s supplier management module allows quality teams to configure tiering criteria directly in the system and assign each supplier to a tier as part of the qualification workflow. The tier assignment drives automated routing: a Tier 1 qualification triggers a multi-step approval workflow that requires quality management sign-off. A Tier 3 qualification follows a shorter path with fewer required steps.

Performance data from incoming inspection, audit findings, and SCAR records feeds automatically into each supplier’s profile. When it is time for the annual performance review, the quality team pulls a structured data set from the system rather than compiling records from multiple sources. The review is documented in the system with a signature and date, and any tier reclassification is recorded in the supplier’s history.

Upcoming audit dates, certification expiry dates, and annual review deadlines for Tier 1 and Tier 2 suppliers are tracked with automated reminders. Quality teams with large supply bases manage these schedules across the full supplier portfolio without relying on manual calendar tracking.

For companies that have received FDA observations related to inadequate supplier controls, formalizing the tiering system in a QMS platform closes the procedural and documentation gaps that generate those citations. See how supplier risk classification works in Cloudtheapp at cloudtheapp.com/demo.

Conclusion

Supplier risk classification is the organizing principle of an efficient supplier quality program. Without it, quality teams apply the same controls to every supplier regardless of the risk they present, wasting resources on low-risk vendors while potentially under-controlling the suppliers whose failures carry the greatest consequence. A documented, criteria-based tiering system satisfies the regulatory requirement for risk-proportionate purchasing controls and gives quality leadership the data they need to manage supply chain risk intelligently.

This post created by and appeared first on Cloudtheapp

An Approved Supplier List (ASL) is the documented foundation of a regulated purchasing controls program. Under FDA QMSR (21 CFR Part 820) and ISO 13485, manufacturers must evaluate and select suppliers based on their ability to meet specified requirements before those suppliers are used. The ASL records which suppliers have been qualified, for which materials or services, and at what qualification tier. A supplier not on the ASL cannot supply regulated materials without going through a qualification process first. An outdated or poorly maintained ASL creates the same compliance risk as having no list at all.

What is an Approved Supplier List?

An Approved Supplier List is a controlled quality document that identifies every external supplier authorized to provide materials, components, or services used in the design, manufacture, or testing of regulated products. Each entry on the list specifies the supplier, what they are approved to supply, and the scope and basis of their approval.

The ASL answers the question that auditors always ask: how does your quality system prevent unapproved suppliers from entering your supply chain? The answer is the ASL, combined with the purchasing procedure that requires confirmation of ASL status before a purchase order is issued.

Supplier quality management encompasses the ASL and everything connected to it: the initial qualification process, supplier audits, performance monitoring, and requalification decisions. The ASL is the output of all that work, expressed as an approved status in a controlled document.

Why the ASL matters for regulatory compliance

FDA’s QMSR Section 820.50 requires manufacturers to establish and maintain documented procedures for evaluating and selecting suppliers, contractors, and consultants based on their ability to meet specified requirements. The results of evaluations and any follow-up actions must be recorded. The ASL is the primary record of these evaluations.

ISO 13485 Section 7.4.1 has nearly identical language. The standard requires that the type and extent of control applied to the supplier be based on the effect of the purchased product or service on the subsequent realization of product and on the output of those processes. In practice, this means suppliers of critical materials require more intensive qualification and monitoring than suppliers of low-risk commodities.

FDA Form 483 observations and warning letters consistently cite manufacturers for purchasing from unapproved suppliers, for failing to maintain current supplier evaluations, and for having ASLs that do not reflect the actual supply chain in use. These citations often arise not from deliberate violations but from informal purchasing decisions that bypass the quality system.

Step 1: Define the scope of your ASL

Before building the list, the quality team must define which suppliers are within the scope of the ASL. Not every vendor a company buys from needs to be on the ASL. The scope should include:

• Suppliers of raw materials and components that become part of the finished product
• Suppliers of critical packaging materials (primary packaging, device packaging)
• Suppliers of materials used directly in manufacturing (processing chemicals, cleaning agents)
• Contract manufacturers and contract testing laboratories
• Suppliers of calibration services for equipment used in manufacturing or testing
• Suppliers of services that have a direct impact on product quality (sterilization, warehousing of finished goods)

General business vendors, office supplies, IT services, and other non-quality-impacting suppliers are typically not included in the ASL scope. The procedure must define the scope explicitly so purchasing decisions are based on a consistent determination of which suppliers require qualification.

Step 2: Classify suppliers by risk tier

A tiered supplier classification system matches the intensity of qualification and monitoring to the risk that each supplier’s materials or services present to product quality. Most regulated manufacturers use a three-tier system:

Tier 1 (Critical suppliers): Suppliers of materials or services that have a direct and significant impact on product safety, efficacy, or regulatory compliance. Examples: API suppliers, contract sterilization services, primary packaging suppliers, contract testing laboratories performing release testing. Tier 1 suppliers require the most extensive initial qualification, including on-site audits, and the most frequent ongoing monitoring.

Tier 2 (Major suppliers): Suppliers of materials with a defined but indirect quality impact. Examples: secondary packaging suppliers, non-critical components, calibration service providers. Tier 2 qualification typically includes a supplier questionnaire, a review of quality system certifications, and periodic performance review without mandatory on-site audits.

Tier 3 (Standard suppliers): Suppliers of low-risk materials or services with minimal direct quality impact. Examples: laboratory reagents for non-critical tests, indirect process materials. Tier 3 qualification may consist of reviewing supplier quality certifications and conducting incoming inspection to specification, without formal audit requirements.

The tiering criteria must be written into the supplier qualification procedure and applied consistently. Auditors will compare how the company has tiered its suppliers against the actual risk profile of the materials supplied.

Step 3: Conduct initial supplier qualification

Initial qualification is the process of evaluating a new supplier before their first purchase order is placed. The qualification activities and documentation required depend on the supplier’s risk tier.

For Tier 1 suppliers, initial qualification typically includes:

• Completion of a supplier questionnaire covering quality system, regulatory compliance, manufacturing capabilities, and previous audit history
• Review of the supplier’s quality management system certificate (ISO 9001, ISO 13485, or equivalent)
• An on-site supplier audit conducted by qualified personnel from the manufacturer’s quality team
• Review and approval of the supplier’s specifications, test methods, and certificates of analysis format
• Evaluation of first-article samples or first-lot inspection data against specification
• A formal qualification decision documented in the supplier qualification file

For Tier 2 suppliers, on-site audits may be replaced by a documented desk review, but the decision to waive an audit must be justified in the qualification record. For Tier 3 suppliers, a review of quality certifications and confirmed ability to meet specifications may be sufficient.

Every initial qualification generates a qualification record tied to the specific supplier and the specific materials or services they are approved to supply. The qualification record is the basis for the ASL entry.

Step 4: Document the ASL correctly

The ASL is a controlled document, subject to the same document control procedures as SOPs, specifications, and other quality records. The document must have a version number, approval signatures, and an effective date. Changes to the list, adding new suppliers, removing disqualified ones, or changing approval scope, require a documented change record.

A complete ASL entry for each supplier includes:

• Supplier name and primary contact information
• Supplier location (facility address for the approved manufacturing or testing site)
• Materials or services approved for purchase from this supplier
• Risk tier classification
• Qualification basis (date of qualification, type of qualification conducted)
• Quality system certification status and expiry date
• Date of most recent supplier audit (if applicable)
• Current performance status (active, conditional, probationary, disqualified)
• Next scheduled review or audit date

The approved scope on the ASL must be specific. Approving a supplier “for all raw materials” is not acceptable for regulatory purposes. Each material or category of materials must be specifically enumerated. A supplier approved to provide excipient grade lactose is not automatically approved to provide API-grade materials without a separate qualification for that application.

Step 5: Maintain the ASL through supplier monitoring

An ASL that is not maintained is not a functioning quality control. Supplier status on the list must be reviewed regularly and updated when performance data, audit findings, or changes at the supplier’s facility affect their qualification status.

Regular maintenance activities include:

Annual performance reviews. Each Tier 1 and Tier 2 supplier should receive a documented annual performance review that summarizes their nonconformance rate, on-time delivery, complaint history, and SCAR closure record for the review period. The outcome of the review confirms, modifies, or removes their approved status.

Periodic requalification audits. Tier 1 suppliers typically require an on-site audit every one to three years, depending on their criticality and performance history. The audit schedule must be documented and executed.

Notification of supplier changes. Qualified suppliers in regulated industries are required to notify their customers of significant changes to their processes, materials, or facilities that may affect the quality of supplied goods. The ASL procedure should include a mechanism for receiving and reviewing supplier change notifications and triggering requalification when needed.

Monitoring of certificate of analysis trends. Incoming CoA data over multiple lots can reveal gradual drift in supplier processes before a lot actually fails incoming inspection. Quality teams that track CoA values over time catch supplier process problems earlier than those that review each lot in isolation.

Handling supplier changes: adding, modifying, and removing entries

Adding a new supplier to the ASL requires completing the initial qualification process and creating a qualification record before the ASL entry is created. Shortcutting this process, such as placing a purchase order and then retroactively qualifying the supplier, is a recurring FDA citation.

Modifying a supplier’s approved scope, for example, expanding an existing approved supplier to cover additional materials, requires a supplemental qualification assessment for the new materials. The existing qualification for other materials does not automatically transfer.

Removing a supplier from the ASL happens when a supplier fails requalification, fails to respond adequately to a supplier corrective action request, or the company decides to stop using them for other reasons. Disqualification must be documented with the reason for disqualification. If the supplier has materials currently in incoming inventory or in process, the quality team must decide how to handle those lots. Simply removing the supplier from the list without addressing outstanding inventory creates a gap in the quality record.

The connection between the ASL and purchasing procedures

The ASL is only as effective as the purchasing procedure that enforces it. The purchasing procedure must require that every purchase order for a regulated material or service is checked against the ASL before the order is placed. This means the purchasing team, not just quality, needs to understand the ASL requirement and have access to current ASL status for every supplier they use.

In a paper-based or spreadsheet-driven system, this enforcement is difficult. Purchasing teams work quickly, and checking a separate controlled document before every purchase order requires discipline and is often skipped under time pressure. An integrated QMS that surfaces ASL status at the point of purchase order creation removes the manual check requirement and makes compliance the default behavior.

How Cloudtheapp manages the Approved Supplier List

Cloudtheapp’s supplier quality module maintains the ASL as a live, controlled record within the QMS. Each supplier has a profile that records their qualification status, approved materials, audit history, performance metrics, and certification expiry dates. The ASL status updates automatically when a qualification record is closed or when a SCAR drives a status change.

When a purchase request is created in the system, the supplier’s current ASL status is visible to the purchasing team in real time. If a supplier is not on the ASL for the requested material, the system flags the request before it reaches the purchase order stage. This prevents the informal workarounds that generate FDA citations.

Supplier performance data from incoming inspection records feeds directly into the supplier’s profile, giving the quality team a rolling view of each supplier’s nonconformance rate without manual data compilation. Annual performance reviews are generated from this data rather than built from scratch.

For companies managing dozens of Tier 1 suppliers with audit schedules, certification expiry dates, and SCAR follow-up timelines, a spreadsheet-based ASL quickly becomes unmanageable. Cloudtheapp brings all of that into a single controlled system with automated reminders for upcoming audits and certification renewals. See how the supplier qualification module works at cloudtheapp.com/demo.

Conclusion

An Approved Supplier List is not a document that gets built once and filed. It is a living record that reflects the current state of a company’s qualified supply chain. Building it correctly means defining scope, classifying suppliers by risk, conducting appropriately intensive initial qualification, and documenting the approval basis for each supplier entry. Maintaining it correctly means conducting periodic reviews, tracking performance data, and keeping the list current when suppliers change or are disqualified. The companies that handle this well treat the ASL as a quality control, not an administrative task.

This post created by and appeared first on Cloudtheapp

Raw materials qualification is the process of verifying that incoming materials meet predefined specifications before they enter the manufacturing process. FDA’s CGMP regulations (21 CFR Parts 211 and 820) and ISO 13485 both require documented incoming acceptance activities, supplier qualification, and identity testing for materials used in regulated products. A compliant raw materials qualification program includes written specifications for every material, a defined incoming inspection procedure, laboratory testing where required, and a documented decision to accept or reject each lot. Materials released without proper qualification are one of the more consistent sources of FDA Form 483 citations in pharmaceutical and medical device manufacturing.

What is raw materials qualification?

Raw materials qualification covers two related but distinct activities. The first is supplier qualification: the process of evaluating and approving a supplier before their materials enter the supply chain. The second is incoming inspection and acceptance: the per-lot testing and review that happens when a shipment arrives at the facility.

In pharmaceutical manufacturing, “raw materials” typically refers to active pharmaceutical ingredients (APIs), excipients, processing aids, primary packaging materials, and cleaning agents that contact the product or primary container. In medical device manufacturing, raw materials include component materials, sub-assemblies, chemicals used in processing, and any material that becomes part of the finished device.

Supplier quality management and incoming materials acceptance are two sides of the same program. A strong supplier qualification program reduces the testing burden at incoming inspection. A weak supplier program increases the testing required at the receiving dock to compensate for unknown supplier capability.

Regulatory requirements: FDA CGMP (21 CFR Part 211)

For pharmaceutical manufacturers, 21 CFR Part 211 Subpart E covers the control of components and drug product containers and closures. The key requirements:

Section 211.80 — General requirements. Written procedures describing the receipt, identification, storage, handling, sampling, testing, and approval or rejection of components must be available and followed.

Section 211.82 — Receipt and storage. Components must be stored under quarantine until tested or examined and released. Each shipment must be examined for identity, condition of containers, and any evidence of contamination.

Section 211.84 — Testing and approval. At least one test for identity must be conducted on each lot of each component before use. This is a hard requirement: FDA does not accept manufacturer certificates of analysis (CoA) as a substitute for identity testing unless a validation study has been conducted proving that the supplier’s CoA is reliable for that specific material and supplier.

Section 211.86 — Use of approved components. Only components that have been released by the quality unit may enter manufacturing. This means the release decision must be documented in the quality system before the material moves to production.

Section 211.87 — Retesting of approved components. Components that have been in storage for a defined period must be retested for conformance before use. The retesting intervals should be based on stability data for the specific material.

Regulatory requirements: FDA QMSR (21 CFR Part 820)

For medical device manufacturers, the Quality Management System Regulation (21 CFR Part 820) addresses incoming materials through purchasing controls (Section 820.50) and receiving, incoming inspection, and testing (Section 820.80).

Section 820.80(b) requires that incoming product not be used or processed until it has been inspected or otherwise verified as conforming to specified requirements. The methods and extent of incoming inspection must be based on risk, with higher-risk components receiving more intensive inspection.

Critically, the regulation allows manufacturers to use supplier data as part of their incoming inspection approach, provided they have established through supplier qualification that the supplier’s data is reliable. This creates a tiered incoming inspection model: fully qualified suppliers with strong track records may support a reduced incoming testing regime, while new or lower-performing suppliers receive more intensive lot-level testing.

ISO 13485 requirements for incoming materials

ISO 13485 Section 7.4.3 covers verification of purchased product. Manufacturers must establish and implement inspection or other activities necessary to ensure that purchased product meets specified purchase requirements. The section explicitly states that the type and extent of inspection must be based on the results of supplier evaluation and the risk associated with the purchased product.

ISO 13485 requires that the basis for the incoming inspection approach, including the rationale for reduced inspection where applied, be documented. If a manufacturer has qualified a supplier to the point where they rely heavily on supplier CoA data without independent testing, that qualification basis must be documented and periodically reviewed.

Section 7.4.1 establishes the broader supplier evaluation and selection framework. Suppliers must be evaluated on their ability to provide product that meets requirements. The results of evaluations and follow-up actions must be recorded.

Identity testing: the requirement that many companies miss

Identity testing is the test that confirms a material is what the label says it is, typically using a physical or chemical method that is specific to the material. For pharmaceutical raw materials under 21 CFR Part 211.84, FDA requires at least one identity test on every incoming lot without exception.

FDA has repeatedly issued 483 observations to pharmaceutical manufacturers for relying solely on supplier certificates of analysis as the identity test. A CoA is not an identity test; it is a document. The regulations require an independent test performed on the material received, not a review of a document describing tests performed elsewhere.

Common identity test methods include:

• Infrared spectroscopy (IR/FTIR) for organic materials and polymers
• High-performance liquid chromatography (HPLC) for APIs and complex chemicals
• Wet chemical tests specified in pharmacopeial monographs (USP, EP, JP)
• Near-infrared (NIR) spectroscopy with validated reference libraries

For medical device materials under 21 CFR Part 820, identity testing is not explicitly required for every lot in the same way as pharmaceutical CGMP. But the risk-based incoming inspection requirement still demands that manufacturers define what verification is appropriate for critical materials. For a material whose identity is critical to device safety, an identity test on incoming lots is consistent with a risk-based approach.

Specifications: the foundation of incoming inspection

No incoming inspection program can function without written specifications. A specification defines what the material must be in order to be accepted. Incoming inspection is the process of comparing what arrived to what the specification requires.

A complete raw material specification typically includes:

• Material name, grade, and intended use
• Physical properties (appearance, particle size, density, viscosity as applicable)
• Chemical identity (assay, specific tests, pharmacopeial monograph reference)
• Purity limits (related substances, heavy metals, water content as applicable)
• Microbiological limits where applicable
• Packaging and labeling requirements
• Storage conditions and retest interval
• Approved supplier list reference

Specifications must be established before the first lot of a material is released for use, not written retroactively to match what arrived. FDA inspectors look for evidence that specifications were approved through the quality system before manufacturing began, not created after the fact.

The approved supplier list and incoming inspection

The supplier quality management program provides the context within which incoming inspection operates. Every material in the incoming inspection program should have a defined list of approved suppliers. Materials from unapproved suppliers, or from approved suppliers for unapproved materials, should not enter the incoming release process until a supplemental qualification review is completed.

The approved supplier list integrates directly with incoming inspection in two ways:

First, it defines who may supply each material. If a CoA arrives from a supplier not on the approved list for that material, the shipment should be quarantined and the supplier qualification team notified before the lot moves through the inspection process.

Second, the supplier’s qualification tier influences the intensity of incoming inspection. A fully qualified supplier with a consistent track record of conforming material may support a skip-lot testing approach, where not every lot is tested to the full specification. A provisional supplier, or one with recent nonconformances, requires full lot testing until their performance is re-established.

Sampling plans for incoming inspection

Sampling plans define how many units from a lot are selected for inspection and what the accept/reject criteria are. A statistically sound sampling plan gives the inspection program a defensible basis for concluding that a lot meets specification based on the sample tested.

Common sampling frameworks used in regulated industries include ANSI/ASQ Z1.4 for attribute sampling (pass/fail tests) and ANSI/ASQ Z1.9 for variable sampling (numerical measurements). Many companies also use risk-based sampling plans that allocate inspection intensity based on the criticality of the material and the supplier’s historical performance.

The sampling plan must be written into the incoming inspection procedure and reviewed by quality assurance. Ad hoc decisions about how many samples to take are not acceptable for regulated materials.

Quarantine, hold, and disposition

Every incoming lot must go through a defined quarantine and disposition process. Quarantine prevents materials from entering manufacturing before the inspection decision is made. Disposition is the quality unit’s documented decision to accept or reject the lot.

Physical quarantine means the material is stored in a separate location, or is physically labeled and segregated, in a way that prevents unauthorized use. Electronic quarantine, enforced through a QMS system that prevents production work orders from drawing on uninspected inventory, is also acceptable when the system has been validated for this purpose.

The disposition decision must be made by a qualified quality representative and documented with a signature and date. A lot that fails incoming inspection must be formally rejected and either returned to the supplier or destroyed under documented procedures. Rejected materials must not be accessible to production.

Documentation and records

FDA and ISO 13485 require that incoming inspection records be maintained for a defined retention period. Complete incoming inspection records include:

• Supplier and lot identification
• Date received
• Quantity received
• Inspection or test results
• Reference to the relevant specification
• Name or signature of the inspector
• Disposition decision (accept or reject) and the name or signature of the quality unit representative who made it

These records must be linked to the manufacturing batch records that use the material, creating traceability from the incoming lot through to the finished product. If a problem is discovered in a finished product, this traceability chain allows the quality team to identify all batches that used the same incoming lot.

How a QMS platform supports raw materials qualification

Managing incoming inspection through paper-based forms or disconnected spreadsheets creates traceability gaps and slows the release process. A modern QMS integrates incoming inspection with the broader supplier qualification and materials management program.

Cloudtheapp’s platform handles the full incoming materials workflow: from supplier approval status verification at the point of receipt, through the structured inspection record, laboratory test entry, and disposition decision, to final release and linkage to the inventory record. Each step in the process is tracked in real time, and the system prevents materials from moving to production without a completed release decision in the record.

The platform’s supplier qualification module maintains the approved supplier list, supplier performance scores, and audit history. When incoming inspection identifies a nonconformance, the system routes a nonconforming material record to the appropriate quality reviewer and links it to the supplier’s performance data. If the nonconformance triggers a supplier corrective action request, the SCAR record is created from within the incoming inspection record with no re-entry required.

For companies that have experienced FDA 483 observations related to incoming inspection, particularly around identity testing documentation or missing lot release records, a structured QMS platform closes the documentation gaps that manual processes leave open. See how Cloudtheapp manages raw materials incoming acceptance at cloudtheapp.com/demo.

Conclusion

Raw materials qualification is a regulatory requirement and a quality system foundation. FDA’s identity testing requirement, the approved supplier list, written specifications, documented sampling plans, and formal disposition records are not optional elements of the program. They are the components that FDA inspectors and ISO auditors check first when reviewing a company’s incoming materials controls. Companies that build these components correctly, and support them with a QMS that enforces the process, produce consistent documentation and avoid the inspection findings that plague manufacturers who manage incoming inspection informally.

This post created by and appeared first on Cloudtheapp

This guide covers how to build and run a SCAR program that meets FDA and ISO 13485 expectations, drives real supplier improvement, and holds up to audit scrutiny.

What is a Supplier Corrective Action Request (SCAR)?

A Supplier Quality Management (SQM) SCAR is a formal written request issued to a supplier when a quality failure — a nonconformance, out-of-spec delivery, process deviation, or audit finding — requires documented investigation and corrective action on the supplier’s side.

Unlike an informal complaint or phone call, a SCAR creates a documented record: the nature of the failure, what the supplier did to investigate it, what root cause they identified, what actions they took, and how they verified the actions were effective. That record is what FDA investigators and ISO auditors look for when they evaluate your supplier controls.

A SCAR differs from an internal CAPA in that it is directed outward. Your QMS captures the supplier’s response and ties it back to your incoming inspection records, approved supplier list, and risk classification. The two processes are linked — a SCAR can trigger an internal CAPA if the supplier failure affected released product.

When FDA and ISO 13485 Require a SCAR

Neither FDA’s Quality Management System Regulation (QMSR, 21 CFR Part 820) nor ISO 13485 uses the term “SCAR” explicitly. Both, however, require manufacturers to maintain procedures for evaluating and controlling suppliers, monitoring supplier performance, and taking action when suppliers fail to meet requirements.

ISO 13485 Section 7.4 requires organizations to establish and maintain documented procedures for supplier evaluation, selection, and re-evaluation. When a supplier fails to meet purchasing requirements, the organization must take appropriate and proportionate actions — and document them. Section 8.5.2 (Corrective Action) applies equally to supplier-caused nonconformances as it does to internal ones.

Under QMSR, 21 CFR 820.50 requires documented supplier selection criteria and ongoing evaluation. FDA investigators routinely review whether manufacturers actually follow up on supplier nonconformances and whether those follow-ups produce evidence of real improvement.

In practice, a SCAR is the mechanism that satisfies both frameworks. It creates the paper trail that shows your organization identified a supplier failure, required an investigation, received a response, evaluated it, and verified effectiveness.

The 7-Step SCAR Process

Step 1: Identify the trigger

A SCAR is triggered by a specific event. Common triggers include:

• Incoming inspection rejection — material fails dimensional, chemical, or visual checks
• In-process detection — nonconforming material identified after release from receiving
• Customer complaint linked to a supplier component
• Supplier audit finding — a significant finding from an on-site or remote audit
• Out-of-specification (OOS) result traceable to a raw material or component
• Repeat occurrence — the same type of failure from the same supplier within a defined window (commonly 12 months)

Not every supplier nonconformance warrants a SCAR. Minor, isolated issues may be handled through informal communication. Your procedure should define the severity thresholds and repeat-offense criteria that make a SCAR mandatory.

Step 2: Issue the SCAR

The SCAR document — whether paper or electronic — should capture:

• Supplier name, address, and contact
• Part number, lot number, and purchase order reference
• Description of the nonconformance, including measurements or test data
• Applicable specification or acceptance criteria that was violated
• Quantity affected and disposition (return to supplier, scrap, rework)
• Requested response date (30 days is standard; 14 days for critical issues)
• Required sections: containment, root cause, corrective action, preventive action, verification plan

Send the SCAR to the supplier’s designated quality contact, not just a sales rep. In regulated industries, routing a SCAR through commercial channels delays response and creates confusion about who owns the quality record.

Step 3: Require immediate containment

Before root cause analysis begins, the supplier should confirm containment. This means:

• Quarantine of any affected inventory at their facility
• Identification of whether nonconforming product was shipped to other customers
• Interim controls to prevent further shipments of potentially affected material

Your team should confirm containment on your side as well — checking whether affected lots are in your own warehouse, in-process, or in distributed product.

Step 4: Evaluate the root cause investigation

This is where most SCAR programs fail. Suppliers submit a response that says “operator error” or “we will retrain our staff,” and quality teams accept it and close the SCAR. That is not a root cause — it is a symptom. A year later, the same failure reappears.

A credible root cause investigation should:

• Use a structured methodology — 5-Why, fishbone (Ishikawa), or fault tree analysis
• Identify the specific process or system failure, not the person who made the error
• Distinguish between the direct cause, the contributing causes, and the systemic cause
• Include supporting data — measurements, inspection records, process parameters

When you receive a supplier response, ask: if this root cause is real, why did the failure not happen on every part? If they can answer that clearly, the root cause is plausible. If they cannot, send the SCAR back for further investigation.

Step 5: Review and accept the corrective action plan

The supplier’s corrective action must address the root cause, not the symptom. Acceptable corrective actions include process changes, updated inspection procedures, control plan revisions, equipment calibration corrections, and procedure rewrites. Unacceptable responses include “we will be more careful” or “we added a visual check” without any documented change to the process or system.

Review the corrective action for:

• Specificity — what exactly changed, where, and when
• Ownership — who is responsible for implementation
• Evidence — what records will confirm the action was taken
• Timeline — when implementation is complete

If the corrective action requires a process change, confirm whether your supplier agreement or your QMS requires formal notification of Process Change Notifications. Some changes at a supplier site may require your review and approval before implementation.

Step 6: Verify effectiveness

The corrective action is not complete when the supplier says it is complete. It is complete when you have evidence the failure rate dropped. Effectiveness verification options include:

• Enhanced incoming inspection of subsequent lots over a defined period
• Review of the supplier’s internal inspection data from production after the change
• A follow-up audit — either on-site or remote — that reviews the changed process
• Statistical process control data from the supplier showing the process is now in control

Define the verification criteria in advance: what result, over what sample size or time period, constitutes success. Do not let SCARs sit in “effectiveness pending” status indefinitely. Set a maximum verification window, and if the criteria are not met, escalate.

Step 7: Close and document

Closure requires your quality team — not the supplier — to formally close the SCAR in your system. The closure record should reference: the original nonconformance, the root cause accepted, the corrective action implemented, the verification result, and the date of closure. This record becomes part of your audit trail for this supplier.

Update your approved supplier list and supplier scorecard to reflect the SCAR history. A supplier with three unresolved SCARs in 12 months is a different risk profile than one with zero.

Common SCAR mistakes that invite FDA observations

Accepting inadequate root causes

FDA investigators look at whether you accepted a supplier’s root cause analysis or challenged it. When a SCAR says “retraining” and you closed it without verification data, that tells the investigator your SCAR process is procedural theater rather than a quality control tool.

No effectiveness verification

ISO 13485 Section 8.5.2(f) explicitly requires verification that corrective actions did not adversely affect the ability to meet requirements. Effectiveness checks are not optional. A common FDA 483 observation reads: “Firm failed to verify the effectiveness of corrective actions taken for supplier nonconformances.”

SCARs not linked to your internal CAPA system

If a supplier failure resulted in nonconforming product reaching your process or your customers, that is an internal quality event as well. Your CAPA system should capture what your organization did in response — not just what you asked the supplier to do. Missing that linkage is a gap auditors find frequently.

Inconsistent triggering criteria

If your procedure says SCARs are required for all Class 1 and Class 2 rejections but your records show some Class 1 rejections were handled informally, that is a procedure non-compliance. Document your triggering criteria clearly and apply them consistently.

Verbal closure

Closing a SCAR because you “called the supplier and they said it was fixed” does not constitute documented evidence. Closure must be based on objective evidence in your QMS — not phone calls.

How to set SCAR response time requirements

Standard practice in regulated industries distinguishes between severity tiers:

• Critical (potential patient safety impact, risk of product recall): 24-hour containment confirmation, 14-day root cause, 30-day corrective action plan
• Major (significant nonconformance, process failure): 3-day containment, 30-day root cause and corrective action plan
• Minor (isolated occurrence, low risk): 30-day response with root cause and corrective action

Include these response time requirements in your supplier agreements and quality agreements. A supplier who does not know the expected response time is more likely to delay or deprioritize. Build non-response escalation triggers into your procedure — for example, if a supplier does not respond within seven days of a critical SCAR, escalate to supplier re-evaluation or temporary hold on new purchase orders.

Linking SCARs to supplier performance metrics

A SCAR should not exist in isolation from your broader supplier management program. Each SCAR contributes to your supplier scorecard. Track:

• SCAR frequency per supplier per period
• Average response time against required response time
• Rate of accepted versus rejected root cause submissions
• Effectiveness verification pass rate
• Repeat nonconformances after SCAR closure

Suppliers with high SCAR frequency or poor response quality should trigger re-evaluation under your approved supplier list criteria. Some organizations define thresholds: three SCARs in 12 months triggers a supplier audit; five within 24 months triggers re-qualification or disqualification proceedings.

Using your QMS to manage SCARs

Paper-based SCAR workflows have two problems that become critical at scale: you cannot systematically track status across dozens of open SCARs, and you cannot easily demonstrate to an auditor the full history of a supplier’s SCAR performance over time.

A purpose-built Supplier Quality Management module in a modern eQMS handles this automatically. Cloudtheapp’s Supplier Corrective Action Request application lets you issue SCARs directly to suppliers — the supplier receives a notification, completes their investigation and response inside your QMS, and the entire record is captured with timestamps, audit trail, and electronic signatures. No email chains, no disconnected spreadsheets, no version confusion.

When a SCAR triggers an internal CAPA, Cloudtheapp creates the linkage automatically. Auditors can see the full chain: the supplier nonconformance, the SCAR issued, the supplier’s response, your verification record, and the internal corrective action your team took — all in one connected record.

Ready to see how Cloudtheapp handles supplier quality management end to end? Book a demo to walk through the SCAR application with a Cloudtheapp specialist.

SCAR and your approved supplier list

Your approved supplier list is only meaningful if you use SCAR data to inform re-evaluation decisions. ISO 13485 requires periodic re-evaluation of approved suppliers. That re-evaluation should include SCAR history: how many SCARs were issued, how the supplier responded, whether effectiveness was verified, and whether repeat failures occurred.

A supplier who consistently responds quickly, provides credible root cause analyses, and has no repeat failures is a low-risk supplier. A supplier who routinely submits inadequate root causes, misses response deadlines, and shows repeat failures on the same failure mode is a high-risk supplier — regardless of how long they have been on your approved list.

Documenting SCARs for inspection readiness

During an FDA inspection, you may be asked to produce all supplier corrective action requests issued within the past two years, along with evidence that each was resolved. That is a straightforward request if your QMS captures everything. It is a two-day scramble if SCARs live in email folders and shared drives.

Your SCAR records should be retrievable by: supplier name, date range, part number, severity level, and status (open, pending verification, closed). Each record should be complete — from the initial trigger through the closure sign-off — without needing to pull supporting documents from other systems.

If your current QMS cannot produce that report in under five minutes, that is a gap worth addressing before your next inspection.

Summary

A well-run SCAR process does three things: it forces suppliers to investigate failures seriously, it gives your quality team documented evidence of supplier controls, and it creates the data you need to make rational supplier risk decisions over time. The seven steps — trigger, issue, contain, investigate root cause, review corrective action, verify effectiveness, close — are not bureaucratic checkboxes. They are each a specific control point that prevents the same failure from recurring.

The difference between a SCAR program that satisfies auditors and one that actually reduces supplier-related quality failures is whether you challenge inadequate root causes, verify effectiveness with data, and use SCAR history in your supplier re-evaluation. Most programs do the first two inconsistently and skip the third entirely.

Want to see how Cloudtheapp’s 60+ quality and compliance applications connect supplier SCARs, CAPAs, incoming inspection, and your approved supplier list in one platform? Schedule a demo today.

This post created by and appeared first on Cloudtheapp

This guide covers what a QMS for contract manufacturers must include, how FDA and ISO requirements apply to CMOs, and how modern electronic QMS platforms reduce the burden of managing multi-client compliance without multiplying headcount.

What makes contract manufacturer QMS requirements different

A brand owner’s QMS is built around its own products, its own processes, and its own regulatory submissions. A contract manufacturer’s QMS must do all of that and accommodate external client requirements that may conflict, overlap, or exceed the CMO’s own baseline.

Three specific pressures make this difficult.

First, quality agreements with clients create contractual QMS obligations. Under FDA’s guidance on quality agreements for contract facilities (applicable under 21 CFR Part 211 for pharmaceutical manufacturers and 21 CFR Part 820 / QMSR for medical device CMOs), the CMO and the contracting company must define in writing which quality activities each party owns. If the agreement assigns change control approval to the client, the CMO’s QMS must enforce that workflow, even when the CMO’s own internal process would allow the change to proceed faster.

Second, multi-client environments create document control complexity. A CMO producing pharmaceutical drug products for three clients may need three separate sets of batch records, three separate deviation procedures, and three separate validation packages, all running in parallel. Without a configurable QMS, this typically means spreadsheets, shared drives, and a quality team spending more time managing version control than managing quality.

Third, supplier qualification does not stop at the CMO’s door. Brand owners often require access to the CMO’s Supplier Quality Management records for raw materials and components. The CMO must be able to demonstrate, on short notice, that its material suppliers are qualified, that certificates of analysis are current, and that any supplier changes were communicated to clients before implementation.

FDA requirements for contract manufacturers

FDA’s QMSR (21 CFR Part 820, effective February 2026) aligns the U.S. medical device QMS regulation with ISO 13485:2016. For medical device CMOs, this means the full QMSR framework applies regardless of whether the CMO holds its own 510(k) or PMA. If the CMO manufactures, packages, or labels devices, it is a “manufacturer” under FDA’s definition and subject to QMSR inspection.

For pharmaceutical CMOs, 21 CFR Part 211 (cGMP for finished pharmaceuticals) applies. FDA has also issued specific guidance on quality agreements for pharmaceutical contract manufacturing operations, making the written quality agreement a regulatory expectation rather than just a commercial practice.

Key FDA requirements CMOs must satisfy include:

• Management responsibility: The CMO must maintain its own quality policy, quality objectives, and management review process. It cannot outsource quality system oversight to the brand owner.
• Document and record control: All documents and records, including client-specific batch records, must be controlled, versioned, and retrievable. FDA inspectors will ask for records by product and by lot number during inspections.
• CAPA: Deviations, nonconformances, and out-of-specification results that occur during contract manufacturing must feed into the CMO’s Deviation CAPA system. The quality agreement must specify whether the client receives CAPA notifications and within what timeframe.
• Change control: Any change to a manufacturing process, equipment, or material that could affect a client’s product requires prior notification or approval, depending on the quality agreement terms. The CMO’s change control SOP must reflect these obligations. Using a Process Change Notification workflow ensures clients are informed before changes go live.
• Supplier qualification: The CMO is responsible for qualifying suppliers of materials used in contract manufacturing. The brand owner may perform overlapping qualification but cannot substitute for the CMO’s own supplier program.

FDA inspectors conducting QMSR inspections at CMO facilities increasingly look for evidence that the CMO understands which products it manufactures are subject to which requirements, and that the QMS adapts to those requirements rather than applying a one-size-fits-all process.

ISO 13485 requirements for contract manufacturers

ISO 13485:2016 Section 4.1 addresses outsourced processes explicitly. When a brand owner outsources manufacturing to a CMO, the brand owner remains responsible for ensuring the outsourced process conforms to the standard. But the CMO also operates under ISO 13485 if it is certified or required to be by its clients.

For CMOs seeking or maintaining ISO 13485 certification, several requirements carry particular weight in a contract manufacturing context.

Section 7.4 covers purchasing and supplier control. When the CMO buys raw materials used to make a client’s product, those materials and their suppliers fall under the CMO’s purchasing control requirements. The CMO must define and document the criteria for supplier evaluation and re-evaluation, maintain supplier quality records, and be able to demonstrate that approved supplier lists are current.

Section 7.5 covers production and service provision. CMOs must demonstrate that production processes are carried out under controlled conditions, with validated processes where outputs cannot be verified by subsequent inspection. For sterile device manufacturers or manufacturers of complex pharmaceutical formulations, process validation records must be available during audits.

Section 8.2 covers monitoring and measurement. CMOs performing in-process testing, release testing, or environmental monitoring on behalf of clients must have validated test methods, calibrated equipment, and documented out-of-specification procedures. These records become part of the product’s technical file or device history record.

Quality agreements: what the CMO QMS must enforce

A quality agreement is a contract. It assigns responsibility for specific quality activities between the CMO and the client. From a QMS standpoint, the CMO’s procedures must reflect what the agreement says the CMO is responsible for doing.

Common quality agreement provisions that directly affect CMO QMS workflows include:

Deviation and nonconformance notification timelines. Many agreements require the CMO to notify the client within 24 to 72 hours of a critical deviation. The CMO’s deviation management system must support timed notifications, either automatically or through workflow-triggered tasks.

Change control approval requirements. If the agreement requires client approval before the CMO changes a validated process, the CMO’s change control module must have a mechanism to hold changes in a pending state until client sign-off is documented.

Audit rights. Most quality agreements grant the client the right to audit the CMO’s facility and quality records. The CMO’s audit management system must support multi-party audit scheduling, findings tracking, and CAPA closure documentation. The audit trail for all quality records must be intact and accessible.

Regulatory filing responsibilities. For pharmaceutical CMOs, the agreement must specify who is responsible for submitting Annual Product Reviews, reporting adverse events, and maintaining FDA registration. The CMO’s document management system must be able to segregate records by client product to support these obligations.

Supplier qualification at CMOs: what clients expect to see

When a brand owner audits a CMO, supplier qualification records are among the first items reviewed. The brand owner needs assurance that the materials going into their product come from suppliers the CMO has evaluated, approved, and actively monitors.

A functional supplier qualification program at a CMO typically covers:

Initial qualification. Before a supplier is approved, the CMO should conduct a risk-based assessment that includes a review of the supplier’s quality certifications, a questionnaire or on-site audit depending on the risk level of the material, and testing of incoming samples against specification.

Approved supplier list maintenance. The approved supplier list (ASL) must be documented, controlled, and linked to the QMS so that purchasing cannot place orders with unapproved suppliers. When a supplier is added, modified, or removed, the change must follow a defined process with documentation.

Ongoing monitoring. Certificate of Analysis review for every incoming shipment, periodic re-qualification based on risk level, and tracking of supplier-related deviations and complaints all contribute to ongoing supplier oversight. Any supplier-associated nonconformance should trigger a review of whether the supplier’s approval status needs to change.

Supplier corrective actions. When a supplier causes a quality issue, the CMO needs a formal Supplier Corrective Action Request (SCAR) process. The SCAR documents the problem, the supplier’s root cause analysis, and the corrective actions taken. This record is often reviewed during client audits and FDA inspections.

Document control in multi-client contract manufacturing

Document control at a CMO is more complex than at a brand owner because the CMO must manage both its own procedures and client-specific documents that govern how their products are manufactured, tested, and released.

Common document categories in a CMO QMS include:

• Master batch records (one per product, per client)
• Executed batch records (one per lot, per product)
• Product-specific SOPs covering client-defined manufacturing steps
• Analytical methods and method validation reports by product
• Cleaning validation protocols covering each piece of shared equipment
• Equipment qualification records for any equipment used in a client’s process

Each of these document types must be version-controlled, approved through a defined review and sign-off workflow, and retrievable by product, lot number, or equipment ID. Document change notifications must be directed to the appropriate personnel based on which products or processes a change affects.

Without a configurable QMS, CMOs typically rely on document numbering conventions and spreadsheet trackers that break down as the client roster grows. Electronic QMS platforms with configurable document templates and multi-level approval workflows reduce the time quality teams spend on document administration while improving compliance reliability.

Validation requirements for CMO equipment and processes

Equipment qualification and process validation at CMOs must cover two categories of use: the CMO’s own standard processes and equipment used for one or more clients’ specific products.

For shared equipment, cleaning validation is a recurring requirement. FDA and EU GMP both require demonstrated removal of residues from previous products before shared equipment is used for the next product. For CMOs manufacturing multiple clients’ products on shared filling lines, mixers, or packaging equipment, cleaning validation protocols and execution records must be maintained per product changeover.

Process validation for pharmaceutical CMOs follows FDA’s three-stage approach: process design (Stage 1), process qualification (Stage 2), and continued process verification (Stage 3). CMOs that propose to manufacture a new product for a client must ensure their equipment and process conditions fall within validated ranges before commercial production begins.

For medical device CMOs, process validation under QMSR must cover any process where the resulting output cannot be verified by subsequent inspection or testing. This commonly applies to sterilization, welding, adhesive bonding, and coating processes.

Managing inspections and audits as a contract manufacturer

CMOs face inspections from two directions simultaneously: regulatory agencies conducting their own scheduled or for-cause inspections, and clients exercising their audit rights under quality agreements.

FDA Form 483 observations issued to a CMO can create downstream problems for every client whose products are manufactured there. A manufacturing site placed on import alert or issued a Warning Letter may be unable to ship products until FDA concerns are resolved, which affects every client regardless of whether their specific product was implicated in the finding.

A well-organized CMO QMS supports inspection readiness by maintaining current and accessible records, keeping CAPA timelines on track, and documenting management review outputs that demonstrate the quality system is working as intended. The inspection plan should be reviewed and updated at least annually to reflect current product scope, validated processes, and any changes since the last inspection.

How Cloudtheapp supports contract manufacturer QMS requirements

Cloudtheapp’s AI-powered QMS platform is built for the multi-client, multi-product complexity that defines contract manufacturing. With 60+ configurable applications across document control, CAPA, supplier qualification, audit management, batch records, change control, and more, it lets CMOs build a single QMS that adapts to different client requirements without duplicating infrastructure.

The platform’s no-code configuration tools allow quality teams to create product-specific document templates, client-specific approval workflows, and role-based access controls that keep each client’s records appropriately segregated. Integration capabilities connect the QMS to ERP and LIMS systems, enabling real-time traceability from purchase orders through batch release.

FDA validation documentation is included with every platform update, removing the revalidation burden that typically follows a system upgrade. For CMOs managing multiple client qualification timelines, this means one validation package covers the platform change regardless of how many clients use it.

If you’re evaluating a QMS platform for your contract manufacturing operation, schedule a demo to see how Cloudtheapp handles multi-client document control, supplier qualification, and audit readiness in a single configured system.

Conclusion

A QMS for contract manufacturers must do more than satisfy a single regulatory framework. It must accommodate quality agreement obligations to multiple clients, manage supplier qualification across shared material supply chains, and support inspection readiness from both regulators and client auditors simultaneously. CMOs that build configurable, electronic quality systems rather than paper-based or spreadsheet-driven processes spend less time on administrative overhead and more time on the quality activities that actually reduce risk. The difference shows up in fewer deviations, faster release timelines, and audit reports with fewer findings.

This post created by and appeared first on Cloudtheapp